会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 25. 发明授权
    • Protective recombinant Haemophilus influenzae high molecular weight proteins
    • 保护性重组流感嗜血杆菌高分子蛋白
    • US06849447B2
    • 2005-02-01
    • US10193764
    • 2002-12-11
    • Sheena M. LoosmoreYan-Ping YangMichel H. Klein
    • Sheena M. LoosmoreYan-Ping YangMichel H. Klein
    • A61K39/00C07K14/285C12N1/21C12N15/70C12N15/00
    • C07K14/285A61K39/00C12N15/70
    • Protective high molecular weight (HMW) proteins are produced recombinantly by expression from E. coli by using a promoter effective in E. coli and a nucleic acid molecule which contains a modified operon of a non-typeable strain of Haemophilus. The modified operon contains the portion only of the A region which encodes the mature HMW protein and the complete B and C regions of the operon. Enhanced levels of expression of the HMW proteins can be achieved by including the E. coli cer gene, a further copy of the portion of the A region of the operon encoding the mature protein or both in the expression vector. Nucleotide and deduced amino acid sequences of the hmw1 and hmw2 genes and HMW1 and HMW2 proteins, respectively of several non-typeable Haemophilus influenzae strain have been identified.
    • 通过使用在大肠杆菌中有效的启动子和含有不可逆型嗜血杆菌菌株的修饰操纵子的核酸分子,通过从大肠杆菌表达重组产生保护性高分子量(HMW)蛋白质。 修饰的操纵子仅含有编码成熟HMW蛋白的A区和操纵子的完整B和C区的部分。 可以通过包括大肠杆菌cer基因,编码成熟蛋白质的操纵子的A区的部分的一部分的进一步拷贝或两者在表达载体中来实现HMW蛋白质的增强水平。 已经鉴定了几种不可逆型流感嗜血杆菌菌株的hmw1和hmw2基因和HMW1和HMW2蛋白的核苷酸和推导的氨基酸序列。
    • 28. 发明授权
    • Multi-component vaccine to protect against disease caused by Haemophilus influenzae and Moraxella catarrhalis
    • 用于防止流感嗜血杆菌和卡他莫拉菌引起的疾病的多组分疫苗
    • US06391313B1
    • 2002-05-21
    • US09353617
    • 1999-07-15
    • Sheena M. LoosmoreYan-Ping YangMichel H. KleinKen Sasaki
    • Sheena M. LoosmoreYan-Ping YangMichel H. KleinKen Sasaki
    • A61K39116
    • A61K39/102A61K39/1045A61K2039/55505A61K2039/70Y02A50/466
    • A multi-valent immunogenic composition confers protection on an immunized host against infection caused by both Haemophilus influenzae and Moraxella catarrhalis. Such composition comprises at least four antigens comprising at least one antigen from Haemophilus influenzae, and at least one antigen from Moraxella catarrhalis. Three of the antigens are adhesins. High molecular weight (HMW) proteins and Haemophilus influenzae adhesin (Hia) proteins of non-typeable Haemophilus and a 200 kDa outer membrane protein of Moraxella catarrhalis comprise the adhesin components while the other antigen is a non-proteolytic analog of Hin47 protein. Each component does not impair the immunogenicity of the others. The multi-valent immunogenic composition may be combined with DTP component vaccines, which may also include non-virulent poliovirus and PRP-T, to provide a component vaccine without impairment of the immunogenic properties of the other antigens.
    • 多价免疫原性组合物赋予免疫宿主免受由流感嗜血杆菌和卡他莫拉菌引起的感染的保护。 这样的组合物包含至少四种抗原,其包含来自流感嗜血杆菌的至少一种抗原和至少一种来自卡他莫拉菌的抗原。 三种抗原是粘附素。 不可分型嗜血杆菌的高分子量(HMW)蛋白和流感嗜血杆菌粘附素(Hia)蛋白和卡他莫拉菌的200kDa外膜蛋白包含粘附素组分,而另一种抗原是Hin47蛋白的非蛋白水解类似物。 每个成分不影响其他成分的免疫原性。 多价免疫原性组合物可以与DTP组分疫苗组合,其也可以包括非毒性脊髓灰质炎病毒和PRP-T,以提供组分疫苗,而不损害其他抗原的免疫原性。
    • 30. 发明授权
    • Analog of Haemophilus Hin47 with reduced protease activity
    • 具有减少的蛋白酶活性的嗜血杆菌Hin47的类似物
    • US6147057A
    • 2000-11-14
    • US106466
    • 1998-06-30
    • Sheena M. LoosmoreYan-Ping YangPele ChongRaymond P. OomenMichel H. Klein
    • Sheena M. LoosmoreYan-Ping YangPele ChongRaymond P. OomenMichel H. Klein
    • A61K39/00A61P31/04C07K14/285C12N9/52A01N43/04
    • C07K14/285C12N9/52A61K2039/51A61K39/00C07K2319/00
    • An isolated and purified analog of Haemophilus influenzae Hin47 protein has a decreased protease activity which is less than about 10% of that of natural Hin47 protein and preferably substantially the same immunogenic properties as natural Hin47 protein. An isolated an purified nucleic acid molecule encoding the Hin47 analog may be provided in a recombinant plasmid which may be introduced into a cell which is grown to produce the Hin47 analog. Immunogenic compositions comprising the Hin47 analog and the encoding nucleic acid may be formulated as vaccines for in vivo administration to a host, including a human, to confer protection against diseases caused by a bacterial pathogen, including Haemophilus species, such as Haemophilus influenzae, that produces Hin47 protein or a protein capable of inducing antibodies in the host specifically reactive with Hin47 protein. The Hin47 analog and the encoding nucleic acid also may be employed in diagnostic applications.
    • 分离和纯化的流感嗜血杆菌Hin47蛋白的类似物具有降低的蛋白酶活性,其小于天然Hin47蛋白的约10%,优选与天然Hin47蛋白基本相同的免疫原性。 可以在重组质粒中提供分离的纯化的编码Hin47类似物的核酸分子,所述重组质粒可以被引入生长以产生Hin47类似物的细胞中。 包含Hin47类似物和编码核酸的免疫原性组合物可以配制成用于体内施用于宿主(包括人)的疫苗,以赋予针对由细菌病原体(例如流感嗜血杆菌)产生的细菌病原体引起的疾病的保护, Hin47蛋白或能够诱导与Hin47蛋白特异性反应的宿主中的抗体的蛋白质。 Hin47类似物和编码核酸也可用于诊断应用。